Actinium Pharmaceuticals, Inc. ATNM
of targeted radiotherapies to address significant unmet medical needs in oncology. We are focused on employing a biology-driven approach
to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies.
Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing
toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.0K | — | $81.0K | $1.0M | $1.1M | — | — | — | — | — |
| Cost of revenue | — | — | — | — | $900.0K | — | — | — | — | — |
| Gross profit | — | — | — | — | $244.0K | — | — | — | — | — |
| R&D | $21.1M | $30.0M | $38.7M | $23.1M | $18.0M | $16.1M | $16.6M | $17.1M | $17.7M | $17.8M |
| SG&A | $15.2M | $12.1M | $13.3M | $12.0M | $8.1M | $6.3M | $5.5M | $6.7M | $9.2M | $9.0M |
| Total operating expenses | $36.3M | $42.1M | $52.0M | $35.1M | $26.1M | $22.4M | $22.1M | $23.8M | $26.9M | $26.8M |
| Operating income | -$36.2M | -$42.1M | -$51.9M | -$34.1M | -$25.0M | -$22.4M | -$22.1M | -$23.8M | -$26.9M | -$26.8M |
| Interest expense | — | — | $3.1M | $1.1M | $190.0K | $178.0K | $172.0K | $173.4K | $5.4K | $5.0K |
| Net income | -$33.9M | -$38.2M | -$48.8M | -$33.0M | -$24.8M | -$22.2M | -$21.9M | -$23.7M | -$26.6M | -$24.3M |
| EPS, basic | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | — | — | — | — | — |
| EPS, diluted | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 | -4.40 | -0.22 | -0.40 | -0.50 |
| Shares, diluted (wtd. avg.) | $31.2M | $30.1M | $26.6M | $24.1M | $20.6M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $48.0M | $72.9M | $77.0M | $109.6M | $78.2M | $64.0M | $9.7M | $14.1M | $17.8M | $20.5M |
| Total current assets | $49.4M | $74.5M | $78.3M | $110.9M | $79.7M | $64.9M | $10.1M | $14.3M | $17.8M | $22.4M |
| Property, plant and equipment | $295.0K | $364.0K | $550.0K | $604.0K | $340.0K | $312.0K | $113.0K | $118.8K | $57.4K | $88.5K |
| Total assets | $51.8M | $76.9M | $81.4M | $114.2M | $80.4M | $66.4M | $11.7M | $14.9M | $18.3M | $22.5M |
| Accounts payable | $7.2M | $7.6M | $8.0M | — | — | $4.3M | $4.6M | $5.8M | $4.7M | $4.2M |
| Total current liabilities | $8.0M | $8.1M | $8.5M | $10.6M | $6.8M | $4.8M | $5.3M | $6.1M | $4.7M | $4.5M |
| Total liabilities | $43.9M | $44.1M | $45.1M | $47.7M | $6.8M | $5.1M | $6.0M | $6.1M | $4.7M | $4.5M |
| Retained earnings | -$409.7M | -$375.8M | -$337.6M | -$288.8M | -$255.7M | -$231.0M | -$208.8M | -$186.9M | -$163.2M | -$136.6M |
| Total equity | $7.8M | $32.8M | $36.4M | $66.5M | $73.5M | $61.3M | $5.6M | $8.8M | $13.7M | $18.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.6M | -$33.1M | -$47.3M | $8.6M | -$20.9M | -$21.6M | -$21.5M | -$20.6M | -$21.6M | -$20.8M |
| Depreciation and amortisation | $173.0K | $197.0K | $207.0K | $152.0K | $105.0K | $54.0K | $54.0K | $50.7K | $55.9K | $77.5K |
| Stock-based compensation | $9.2M | $5.3M | $3.8M | $2.8M | $1.7M | $1.3M | $1.3M | $1.8M | $3.5M | $4.3M |
| Capital expenditure | $104.0K | $11.0K | $153.0K | $366.0K | $133.0K | $253.0K | $64.0K | $96.1K | $24.7K | $60.0K |
| Investing cash flow | -$104.0K | -$11.0K | -$153.0K | -$366.0K | -$133.0K | -$253.0K | -$64.0K | -$96.1K | -$24.7K | -$109.8K |
| Financing cash flow | -$217.0K | $29.3M | $14.9M | $23.1M | $35.2M | $76.2M | $17.1M | $17.0M | $18.8M | $15.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036504.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |